TG Therapeutics, Inc. (NASDAQ: TGTX) a biopharmaceutical company, that focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally is set for a breakout amidst a bullish symmetrical triangle pattern.
Analyst Forecast
According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $40.67, which is an increase of 35.16% from the latest price.
Important Dates
The next confirmed earnings date is Monday, March 3, 2025, before market open.
On How the bullish symmetrical plays out is largely incumbent on the earnings report slated for today Monday March 3, 2025 before the bell.
Analyst Forecast
According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $40.67, which is an increase of 35.16% from the latest price.
Important Dates
The next confirmed earnings date is Monday, March 3, 2025, before market open.
On How the bullish symmetrical plays out is largely incumbent on the earnings report slated for today Monday March 3, 2025 before the bell.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.